Ryan M. Pate

Associate

Austin

"Ryan Pate is a highly regarded associate who frequently acts on fraud and abuse matters."

Chambers USA

Ryan represents hospital systems, medical device manufacturers, pharmaceutical companies and other health care providers and suppliers in complex investigations and litigation, and counsels them on how to navigate regulatory and compliance matters. He is also an accomplished brief writer with a track record of crafting novel and compelling arguments to support our clients in resolving litigation matters.

Recognitions

  • Selected through peer review for inclusion in The Best Lawyers in America© "Ones to Watch" list for Health Care Law, 2023-2025
  • Ranked in Chambers USA as "Associates to Watch" for Texas Healthcare, 2023-2025

Credentials

Education

  • University of Texas School of Law, 2015, J.D., The American Journal of Criminal Law
  • Baylor University, 2012, M.Tax.
  • Baylor University, 2012, B.B.A., Accounting, cum laude

Professional admissions & qualifications

  • Texas

News

News
Individual Award
News release

Reed Smith lawyers named 'Ones to Watch' by Best Lawyers

Blogs

Blogs
Health Industry Washington Watch

OIG Approves Free Companion Diagnostic Testing Program for Enzyme Inhibitor Drug

Blogs
Health Industry Washington Watch

No Criminal Charges for Cooperative Medicare Advantage Organization

Blogs
Health Industry Washington Watch

New Connecticut Law Targets Drug and Device Manufacturers who Employ Sales Representatives for Additional Scrutiny

Blogs
Health Industry Washington Watch

Eighth Circuit Finds “But-For” Causation Standard for AKS-Premised FCA Cases

Blogs
Health Industry Washington Watch

CMS Issues Updated Open Payments FAQs

Blogs
Health Industry Washington Watch

Future of discount safe harbor for prescription drugs remains uncertain

Blogs
Health Industry Washington Watch

Plausibility Pleading in the Digital Age: Federal appellate courts take fresh look at Rule 8 in FCA context

Blogs
Health Industry Washington Watch

FDA issues draft guidance regarding principles for selecting, developing, modifying, & adapting patient-reported outcome instruments for use in medical device evaluation

Blogs
Health Industry Washington Watch

FDA issued guidance on statistical considerations for clinical trials during the COVID-19 public health emergency

1 / 9